Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study
Table 3
Changes in bone markers according to the duration of the disease and steroid combination.
Osteocalcin
Bone ALP
Disease duration
0.009
0.050
6 months
Pretreatment
18.6 ± 13.9
29.3 ± 18.8
Posttreatment
19.6 ± 24.3
25.7 ± 13.0
Difference
1.2 ± 24.1
4.2 ± 17.0
0.058
0.088
6 months
Pretreatment
13.9 ± 19.6
23.4 ± 14.0
Posttreatment
10.1 ± 9.7
18.0 ± 6.4
Difference†
4.9 ± 13.3
5.5 ± 12.4
<0.0001
0.002
Steroid
Combination
Pretreatment
16.5 ± 18.0
27.3 ± 18.0
Posttreatment
13.6 ± 15.6
22.0 ± 10.5
Difference
4.2 ± 18.7
5.4 ± 15.7
0.0002
0.001
Without combination
Pretreatment
15.5 ± 12.1
22.7 ± 9.3
Posttreatment
20.5 ± 30.9
20.9 ± 13.2
Difference
−2.8 ± 22.3
2.1 ± 9.0
0.153
0.275
value represents difference from pretreatment value to posttreatment value within each group. value represents difference of treatment outcome by prevalence duration. †Posttreatment value − pretreatment value.
